nice new high today

– Interim Results in ATTR Patients Show up to 93% Knockdown of TTR with Activity toward Both Wild-Type and Mutant TTR –– Multiple Doses of ALN-TTR02 Generally Safe and Well Tolerated with Once-Every-Four-Week and Once-Every-Three-Week

CAMBRIDGE, MASS. — Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, announced today the achievement of positive clinical results from its Phase II trial of ALN-TTR02, an RNAi therapeutic targeting the transthyretin (TTR) gene for the treatment of TTR-mediated amyloidosis (ATTR). The data were presented today at the 2013 Biennial Meeting of the Peripheral Nerve Society, held June 29 – July 3 in St. Malo, France. Interim results show that multiple doses of ALN-TTR02 led to robust and statistically significant (p<0.001) knockdown of serum TTR protein levels of up to 93%. Knockdown of TTR, the disease-causing protein in ATTR, was found to be rapid, dose dependent, and durable, and similar activity was observed toward both wild-type and mutant protein. In addition, ALN-TTR02 was found to be generally safe and well tolerated in this study.

“These new ALN-TTR02 results are a major milestone in our TTR program, where – for the first time in ATTR patients – we have demonstrated robust knockdown of up to 93% of circulating wild-type and mutant TTR in a multi-dose study. The clinical relevance of lowering circulating TTR has been demonstrated in ATTR patients who have benefited from the elimination of mutant TTR through liver transplantation. In addition, we are very encouraged with the continued safety profile of ALN-TTR02 which has now been extended with this experience in ATTR patients and with multi-dose regimens,” said Jared Gollob, M.D., Vice President, Clinical Research at Alnylam. “This Phase II trial continues in patients receiving a once-every-three-week dosing regimen and we plan to share the complete data set at the International Symposium on Familial Amyloidotic Polyneuropathy in Rio de Janeiro this November.”

“I am very encouraged by these new clinical activity and safety data with ALN-TTR02, an RNAi therapeutic for the treatment of ATTR. Specifically, I am impressed with the potent, rapid, and durable knockdown of both mutant and wild-type TTR, which is important since TTR protein reduction in patients with ATTR has the potential to delay or even reverse disease progression with associated clinical benefits,” said Professor David Adams, M.D., Ph.D., Neurology Department Head at CHU de Bicetre (APHP), Le Kremlin-Bicetre Cedex, France. “I very much look forward to the continued advancement of RNAi therapeutics in clinical trials for the treatment of ATTR, as there are currently few options for patients suffering from this debilitating, progressive disease.”

http://www.heraldonline.com/2013/06/30/4987678/alnylam-reports-positive-phase.html

Tekmira Pharmaceuticals Corp’s “Buy” Rating Reaffirmed at Maxim Group (TKMR)

Posted by: Shayan Afkhami Posted date: June 18, 2013 In: Analyst Articles - US, Investing

Tekmira Pharmaceuticals Corp (NASDAQ: TKMR)‘s stock had its “buy” rating reaffirmed by research analysts at Maxim Group in a report released on Tuesday, TheFlyOnTheWall.com reports. They currently have a $7.00 price target on the stock. Maxim Group’s price objective would suggest a potential upside of 45.83% from the stock’s previous close.

Shares of Tekmira Pharmaceuticals Corp (NASDAQ: TKMR) traded down 1.25% during mid-day trading on Tuesday, hitting $4.74. Tekmira Pharmaceuticals Corp has a one year low of $1.77 and a one year high of $6.78. The stock’s 50-day moving average is currently $4.55.

Tekmira is a leader in the development of therapeutic agents based upon Nobel Prize winning breakthroughs in the field of gene silencing, known as RNA interference (NASDAQ: TKMR).

http://www.mideasttime.com/tekmira-pharmaceuticals-corps-buy-rating-reaffirmed-at-maxim-group-tkmr/26169/

8:01AM Tekmira Pharma provides update on U.S. Government sponsored TKM-Ebola program; funding has been increased by $6.9 mln, from $34.8 mln to $41.7 mln for the first phase of the contract (TKMR) 4.73 : Co announced that its contract with the U.S. Department of Defense (DoD) has been modified to support development plans that integrate advancements in Tekmira's lipid nanoparticle (LNP) formulation and manufacturing technologies, and provide for additional funding for the TKM-Ebola program.

TKM-Ebola, an anti-Ebola viral therapeutic, is being developed under a contract with the U.S. DoD's Joint Project Manager Transformational Medical Technologies (JPM-TMT) Office with a total contract value of ~$140 million.

8:03AM Tekmira Pharma's collaborators at the National Cancer Institute present preclinical data at the AACR; preclinical results indicate that a statistically significant decrease in tumor size was observed in the animals treated with either CSN5 siRNA or a combination of CSN5 and WEE1 siRNA (TKMR) 4.58 : Co announced that its collaboration partner, the National Cancer Institute, will present preclinical data at the annual meeting of the American Association for Cancer Research in a poster session beginning at 8:00 am ET today entitled "Nanoparticle-Based Combinatorial siRNA Therapy against Human Hepatocellular Carcinoma."

The preclinical results summarized in the poster indicate that a statistically significant decrease in tumor size was observed in the animals treated with either CSN5 siRNA or a combination of CSN5 and WEE1 siRNA. The results also indicate that the treatment does not affect the global gene expression in the surrounding liver following siRNA therapy compared to that seen in the tumor tissue, supporting the tumor-specific nature of the effect. Tekmira has an ongoing collaboration with the NCI to identify novel cancer genes for RNAi applications to meet unmet needs

............wow,the volume today was off the charts.Only a .19 move withe that kind of volume?

Y big jump?

SAN FRANCISCO (Reuters) - Unexpected serious side effects arose in a huge study of a Merck & Co long-acting niacin drug aimed at raising good HDL cholesterol, according to data released on Saturday, possibly adding another nail to the coffin of niacin therapy for heart patients.

Merck has already given up on the drug that combines extended-release niacin with an experimental agent called laropiprant, designed to prevent the uncomfortable facial flushing associated with niacin.

When it was announced that the drug called Tredaptive had failed to prevent heart attacks, strokes, death and other complications in heart patients also taking drugs to lower bad LDL cholesterol, Merck said it would not seek U.S. approval and would stop selling it in the dozens of other countries where it was already available.

A European medical journal last week said the drug caused concerning muscle weakness, especially in Asian patients.

But the results presented on Saturday at the American College of Cardiology scientific meeting in San Francisco painted an even more troubling picture of the medicine.

Researchers found patients taking the Merck drug had significantly higher rates of bleeding - 2.5 percent vs. 1.9 percent - and infections - 8.0 percent vs. 6.6 percent - that they called unexpected.

Significantly higher numbers of patients taking Tredaptive also experienced serious health problems that researchers called known side effects of niacin. Those included new onset diabetes - 9.1 percent vs. 7.3 percent - diabetic complications - 11.1 percent vs. 7.5 percent - and gastrointestinal problems - 4.8 percent vs. 3.8 percent.

Niacin, a form of vitamin B, has been used for many years in the belief that its HDL raising powers would help prevent heart attacks and strokes.

Professor Jane Armitage, who led the study called HPS2-Thrive, called the findings disappointing.

"Still," she said, "finding out a drug is not helping people is just as important as finding that it has benefits."

But Dr. Steven Nissen, head of cardiology at Cleveland Clinic, had some serious criticism about the study's design, execution and conclusions, and was not prepared to write off niacin therapy just yet for patients with very low HDL levels.

"Sometimes large and simple trials are large and sloppy trials," he said.

Among his concerns Nissen cited the very large number of Asians in the study that could have skewed the results because Asians tend to not tolerate high dose niacin. Nissen also said the baseline LDL levels of 66 for patients in the study were unrealistically low and that those with higher LDL levels may have benefited from the drug.

The trial was not designed to show whether the adverse side effects were caused by the niacin or the anti-flushing drug, another potential failing.

But Armitage, a professor at the University of Oxford, said the results were consistent with an earlier failed niacin study that did not include laropiprant and that many of the side effects are known to be associated with niacin.

"We now know that its adverse side effects outweigh the benefits when used with current treatments," she said.

Nissen was not so sure, saying this was not the final nail in the niacin therapy coffin.

"There are some nails in the coffin. But it doesn't absolutely answer the question," he said of the study. "I don't know that it was the niacin. They may be right, but they may be wrong."

(Reporting by Bill Berkrot; editing by Gunna Dickson)
___________________________________________________________

Merc should pay a visit to Dr Murray and talk about cholesterol.

Echo20

8:02AM Tekmira Pharma believes that current funds on hand, plus expected income will be sufficient to continue product development into 2015 (TKMR) 4.75 : Co announced its key product development, corporate, and partner milestones for 2013. "Looking at our partners, we anticipate results from Alnylam's ALN-TTR02 Phase II trial in mid-2013 and the initiation of a Phase III trial by the end of 2013 and we expect to receive $10 million in milestone payments from Alnylam in 2013. In addition, we are entitled to future royalty payments based on sales of Marqibo, which was recently approved by the FDA. With clarity around the intellectual property protecting our LNP technology platform, we are well-positioned to pursue product, platform and strategic partnering deals," added Dr. Murray.

Financial guidance
Tekmira believes that current funds on hand, plus expected income, including payments received from Alnylam in Q4 2012 and other funds from collaborative partners and the U.S. Government, will be sufficient to continue product development into 2015.

ALN-PCS

Alnylam-MDCO Join for ALN-PCS

by Zacks Equity Research
February 05, 2013

Alnylam Pharmaceuticals Inc. (ALNY - Analyst Report) recently entered into an exclusive global alliance with The Medicines Company (MDCO - Analyst Report) for the development and commercialization of the prior’s ALN-PCS ribo nucleic acid interference (RNAi) therapeutic program.

Currently under development for the treatment of hypercholesterolemia, ALN-PCS RNAi is an important program in Alnylam’s “Alnylam 5x15” strategy.

As per the terms of the collaboration agreement, The Medicines Company will be making an upfront cash payment of $25 million to Alnylam. Alnylam is also eligible to receive up to $180 million on the achievement of development and commercial milestones. The company could also receive scaled double-digit royalties from The Medicines Company on global products sales of the ALN-PCS products commercialized under this agreement.

The collaboration includes ALN-PCS02 and ALN-PCSsc. ALN-PCS02 is an intravenous RNAi therapeutic which completed a phase I trial, whereas ALN-PCSsc, a subcutaneously administered RNAi therapeutic, is currently in pre-clinical development.

Meanwhile, Alnylam is expected to continue with its ALN-PCS program for another one to two years to complete certain pre-clinical and phase I studies. The Medicines Company will be responsible for the development of the candidates from phase II onwards. The Medicines Company will also be responsible for the commercialization of the candidates if the ALN-PCS program is successful.

Earlier this year, Alnylam had provided a brief update on its key “Alnylam 5x15” pipeline, which aims to develop RNAi therapeutic candidates and partner programs for the next couple of years. The company is expecting several study results based on its RNAi therapeutic candidates in the next two years.

We believe that the company is progressing well with its “Alnylam 5x15” pipeline. We expect investor focus to stay on the successful development of the pipeline, though most of them are in early stages of development.

http://www.zacks.com/stock/news/92055/alnylam-mdco-join-for-aln-pcs

April 20, 2012

Tekmira's LNP Technology Enables Alnylam's Positive ALN-PCS Clinical Data

VANCOUVER, British Columbia, April 20, 2012 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today reported that Alnylam Pharmaceuticals, Inc. presented positive clinical results from its Phase 1 clinical trial of ALN-PCS, an RNAi therapeutic targeting PCSK9 for the treatment of severe hypercholesterolemia, which utilizes Tekmira's lipid nanoparticle (LNP) technology and is manufactured by Tekmira.

"We are pleased this new data from the ALN-PCS human clinical trial continues to demonstrate that Tekmira's leading LNP technology is well tolerated and enables RNAi activity in humans. As the evidence of positive data within the RNAi field continues to grow, we believe that Tekmira's LNP technology is a key driver advancing the field towards the commercialization of RNAi therapeutics for a variety of clinical indications," said Dr. Mark J. Murray, Tekmira's President and CEO.

http://investor.tekmirapharm.com/releasedetail.cfm?ReleaseID=666039

nanopatent,

Tomarrow should be interesting.

ECho20

Tekmira's LNP Technology Highlighted in Peer-Reviewed Publication, Cancer Discovery

Results Outline Most Comprehensive Human Experience to Date for RNAi Therapeutics Delivered With Lipid Nanoparticles (LNPs)
Press Release: Tekmira Pharmaceuticals – 8 minutes ago

VANCOUVER, British Columbia, Jan. 31, 2013 (GLOBE NEWSWIRE) -- Tekmira Pharmaceuticals Corporation (TKMR) (TKM.TO), a leading developer of RNA interference (RNAi) therapeutics, announced today that complete study results have been published from a Phase I trial with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of advanced solid tumors with liver involvement, which utilizes Tekmira's lipid nanoparticle (LNP) technology. ALN-VSP is being developed by Alnylam Pharmaceuticals, Inc. (ALNY).

"This published work further validates the longer-term safety and tolerability of Tekmira's industry-leading LNP delivery platform, which is enabling the anti-tumor activity reported in this paper. Our LNP technology, which represents the most widely-used delivery technology in the RNAi field, is driving the advancement of our own product pipeline, including our lead cancer therapeutic TKM-PLK1, as well as the clinical-stage therapeutics of our partners," said Dr. Mark J. Murray, Tekmira's President and CEO.

Tekmira has granted Alnylam a license to use Tekmira's LNP technology to advance RNAi therapeutic products, including the products ALN-VSP, ALN-TTR and ALN-PCS, and Tekmira remains eligible to receive milestones and royalties as Alnylam's LNP enabled products are developed and commercialized. Tekmira will receive a $5 million payment related to initiation of clinical trials for ALN-VSP in China. Alnylam has guided that it expects to report results in mid-2013 from its Phase II study with ALN-TTR02 in patients with ATTR, and anticipates initiating a Phase III pivotal trial of ALN-TTR02 in late 2013. Tekmira will receive a $5 million milestone payment upon ALN-TTR02 entering a pivotal trial and royalties on commercial sales of ALN-TTR.

The most recently published paper is entitled "First-in-Man Trial of an RNA Interference Therapeutic Targeting VEGF and KSP in Cancer Patients with Liver Involvement" and appears as an OnlineFirst publication in the journal Cancer Discovery (Tabernero et al., Cancer Discovery CD-12-0429; Published OnlineFirst January 2013). More detailed information about the Phase I Clinical Trial and Extension Study with ALN-VSP can be found in Alnylam's news release dated January 30, 2013, which has been posted at www.alnylam.com.

About RNAi and Tekmira's LNP

RNAi therapeutics have the potential to treat a broad number of human diseases by "silencing" disease causing genes. The discoverers of RNAi, a gene silencing mechanism used by all cells, were awarded the 2006 Nobel Prize for Physiology or Medicine. RNAi therapeutics, such as "siRNAs," require delivery technology to be effective systemically. Tekmira believes its LNP technology represents the most widely adopted delivery technology for the systemic delivery of RNAi therapeutics. Tekmira's LNP platform is being utilized in multiple clinical trials by both Tekmira and its partners. Tekmira's LNP technology (formerly referred to as stable nucleic acid-lipid particles or SNALP) encapsulates siRNAs with high efficiency in uniform lipid nanoparticles that are effective in delivering RNAi therapeutics to disease sites in numerous preclinical models. Tekmira's LNP formulations are manufactured by a proprietary method which is robust, scalable and highly reproducible, and LNP-based products have been reviewed by multiple FDA divisions for use in clinical trials. LNP formulations comprise several lipid components that can be adjusted to suit the specific application.

About Tekmira

Tekmira Pharmaceuticals Corporation is a biopharmaceutical company focused on advancing novel RNAi therapeutics and providing its leading lipid nanoparticle delivery technology to pharmaceutical partners. Tekmira has been working in the field of nucleic acid delivery for over a decade and has broad intellectual property covering LNPs. Further information about Tekmira can be found at www.tekmirapharm.com. Tekmira is based in Vancouver, B.C.

The Tekmira Pharmaceuticals logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=8319
Forward-Looking Statements and Information
This news release contains "forward-looking statements" or "forward-looking information" within the meaning of applicable securities laws (collectively, "forward-looking statements"). Forward-looking statements are generally identifiable by use of the words "believes," "may," "plans," "will," "anticipates," "intends," "budgets," "could," "estimates," "expects," "forecasts," "projects" and similar expressions, and the negative of such expressions. Forward-looking statements in this news release include Tekmira's strategy, future operations, clinical trials, prospects and the plans of management; RNAi (ribonucleic acid interference) product development programs; Alnylam's ALN-VSP product development program as a treatment for cancer; the development timeline and expected milestone payments associated with Alnylam's ALN-TTR program; the advancement of products that utilize Tekmira's lipid nanoparticle technology; expectations regarding the advancement of multiple product candidates; the quantum and timing of further clinical data being presented for LNP-enabled products; continued innovation and protection of LNP technology; timing of the initiation of clinical trials and release of clinical data from Tekmira's product candidates; the quantum and timing of potential milestone and royalty payments; and the use of lipid nanoparticle technology by Tekmira's licensees.

With respect to the forward-looking statements contained in this news release, Tekmira has made numerous assumptions regarding, among other things: LNP's status as a leading RNAi delivery technology; early results in human clinical trials are indicative of the potential opportunity to treat a variety of disease indications, including cancer; Tekmira's research and development capabilities and resources; the timing and results of clinical data releases and use of LNP technology by Tekmira's development partners and licensees; the time required to complete research and product development activities; the timing and quantum of payments to be received under licenses with Tekmira's collaborative partners including Alnylam; and the sufficiency of budgeted capital expenditures in carrying out planned activities. While Tekmira considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies.

Additionally, there are known and unknown risk factors which could cause Tekmira's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements contained herein. Known risk factors include, among others: the possibility that current and future data from the human clinical trials with ALN-VSP and ALN-TTR02 conducted by Alnylam does not and will not lead to favourable results for Tekmira's products or prospects; the possibility that there will not be further clinical data on LNP-enabled products in the quantum nor timing anticipated by Tekmira, or at all; the possibility that Tekmira may not be able to innovate nor protect its LNP technology; the possibility that other organizations have made advancements in RNAi delivery technology that Tekmira is not aware of; the FDA will not approve the commencement of Tekmira's planned clinical trials or approve the use of Tekmira's products; difficulties, delays or inaccuracies in the progress, timing, results and data from clinical trials and studies; the possibility that Tekmira may not advance any further product candidates; competition from other pharmaceutical or biotechnology companies; Tekmira's development partners and licensees conducting clinical trials and development programs will not result in expected results on a timely basis, or at all; anticipated payments under licenses with Tekmira's collaborative partners, including Alnylam, will not be received by Tekmira on a timely basis, or at all, or in the quantum expected by Tekmira; IND applications may not be filed on a timely basis, pre-clinical trials may not be completed, or clinical trials started, when anticipated or at all; pre-clinical or clinical trials may not generate results that warrant future development of the tested drug candidate; funding from research and product development partners may not be provided when required under agreements with those partners; and Tekmira has not sufficiently budgeted for capital expenditures necessary to carry out planned activities.
A more complete discussion of the risks and uncertainties facing Tekmira appears in Tekmira's annual report on Form 20-F for the year ended December 31, 2011 (Annual Report), which is available at www.sedar.com or at www.sec.gov/edgar.shtml. All forward-looking statements herein are qualified in their entirety by this cautionary statement, and Tekmira disclaims any obligation to revise or update any such forward-looking statements or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, except as required by law.

Contact:
Investors
Jodi Regts
Director, Investor Relations
Phone: 604-419-3234
Email: jregts@tekmirapharm.com
Media
David Ryan
Longview Communications Inc.
Phone: 416-669-7906
___________________________________

Echo20

$87.50

United States Patent Application 20130022649 Yaworski; Ed; et al

January 24, 2013

SNALP FORMULATIONS CONTAINING ANTIOXIDANTS

Abstract
The present invention provides methods of preventing, decreasing, or inhibiting the degradation of cationic lipids and/or active agents (e.g., therapeutic nucleic acids) present in lipid particles, compositions comprising lipid particles stabilized by these methods, methods of making these lipid particles, and methods of delivering and/or administering these lipid particles, e.g., for the treatment of a disease or disorder.

Inventors:
Yaworski; Ed; (Maple Ridge, CA) ; Heyes; James; (Vancouver, CA) ; Judge; Adam; (Vancouver, CA) ; Reid; Stephen; (Surrey, CA) ; MacLachlan; Ian; (Mission, CA)

Assignee:
Protiva Biotherapeutics, Inc.
Burnaby
BC

Claims
1. A method for preventing, decreasing, or inhibiting the degradation of a polyunsaturated cationic lipid present in a nucleic acid-lipid particle, said method comprising: including an antioxidant in said nucleic acid-lipid particle, wherein said antioxidant comprises ethylenediaminetetraacetic acid (EDTA) or a salt thereof, and wherein said nucleic acid-lipid particle comprises a nucleic acid, said polyunsaturated cationic lipid, a non-cationic lipid, and a conjugated lipid that inhibits aggregation of said particle.

http://appft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PG01&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.html&r=1&f=G&l=50&s1=%2220130022649%22.PGNR.&OS=DN/20130022649&RS=DN/20130022649

http://www.patent2pdf.com/pdf/20130022649.pdf

nanopatent,

Good.

I just wanted to make sure that was not recent.

Thanks.

Echo20

Yes!

From SEDAR:

2319634.2
Form 51–102F3
Material Change Report
Item 1 Name and Address of Company
Tekmira Pharmaceuticals Corporation
200 - 8900 Glenlyon Parkway
Glenlyon Business Park
Burnaby, B.C.
V5J 5J8
(“Tekmira”)
Item 2 Date of Material Change
May 30, 2008
Item 3 News Release
A press release was issued by Tekmira through Marketwire on June 2, 2008.
Item 4 Summary of Material Change
Tekmira Pharmaceuticals Corporation (“Tekmira”) announced on June 2, 2008 that it had completed the business combination (the “Business Combination”) with Protiva Biotherapeutics
Inc. (“Protiva”).

Nanopatent

Is the date of June, 2008 correct?

Echo20

Tekmira owns Protiva!

Surf and Nanopatent

What is the NOTICE OF EFFECTIVENESS?

Seems like a lof ot technical papers out recently.

Hidden meanings?

Echo20

Looks like Dr Mark J. Murray has a second company:

Company Overview
Protiva Biotherapeutics, Inc., a development stage biotechnology company, develops nucleic acid based pharmaceutical products. The company focuses on developing products to fight various human diseases, such as cancer, influenza, Ebola, inflammatory diseases, and chronic viral infections. Its products include Pro 1, a tumor cell growth inhibitor, which kills tumor cells and inhibits tumor growth; Pro-101, an siRNA product that acts to inhibit the production of a protein involved in tumor growth; Pro-B, which acts to inhibit the expression of a protein, apolipoprotein B; Pro-EBOV and Pro-MARV that act to inhibit the replication of the Ebola and Marburg viruses; and Stable Nucleic-Acid Lipid P...Detailed Description


1127 41st Avenue East
Seattle, WA 98112
United States
Founded in 2000
26 Employees
Phone:
206-325-2412
www.protivabio.com


Key Executives for Protiva Biotherapeutics, Inc.
Dr. Mark J. Murray
Chief Executive Officer

Mr. Martin C. McConnell
Chief Financial Officer
Dr. Ian MacLachlan
Chief Scientific Officer and Executive Vice President
Dr. Peter Lutwyche
Vice President of Pharmaceutical Development
Compensation as of Fiscal Year 2012.


Tekmira Pharmaceutical

TEKMIRA PHARMACEUTICALS CORPORATION
(Exact name of Registrant as specified in its charter)




British Columbia 2834 980597776
(Province or other Jurisdiction of
Incorporation or Organization) (Primary Standard Industrial
Classification Code Number) (I.R.S. Employer
Identification Number, if any)
100-8900 Glenlyon Parkway
Burnaby, British Columbia
Canada, V5J 5J8
(604) 419-3200
(Address and telephone number of Registrant’s principal executive offices)
National Registered Agents, Inc.
1780 Barnes Blvd. S.W. Bldg. G
Tumwater, Washington 98512-0410
(206) 381-8840
(Name, address (including zip code) and telephone number (including area code) of agent for service in the United States)


Copies to:


Daniel M. Miller
Dorsey & Whitney LLP
Suite 1605, 777 Dunsmuir Street
Pacific Centre
Vancouver, British Columbia
Canada V7Y 1K4

Mark J. Murray
Ian C. Mortimer
Tekmira Pharmaceuticals Corporation
100-8900 Glenlyon Parkway
Burnaby, British Columbia
Canada V5J 5J8
(604) 419-3212
_________________________________________________________

Two companies?

Echo20

Listen to this piece on The Street.comTV from 4 years ago where Cramer is teaching his cohorts how to manipulate a stock. Listen during the first few minutes where Jim says things like: “No one else in the world would admit that,” "I would not say this on TV," “it is blatantly illegal”, “beleaguer all the moron longs”, “feed the bozo reporter” “call Pisani cause you gotta use those guys” “don’t do anything remotely truthful”, “in a few weeks they will know that everything they heard was a lie.”

dia76a

Can you add some more information on that statement on the Creamer pump and dump.

Echo20

Cramer pump and dump is over.

Looks like Franklin Templeton will be selling TKMR.

Great.

Echo20

Surf144, Nanopatent

The new PR for TKMR looks like Franklin
Templeton is investing in TKMR.

Growth Fund?

Big Investor?

Looks good.

Could that be OFF THE SHELF?

Echo20

TKMR- Jim Cramer,1-10-2013
Tekmira Pharmaceuticals (TKMR)

This company is engaged in a biopharmaceutical business focused on advancing novel RNA interference therapeutics and providing its lipid nanoparticle delivery technology to pharmaceutical partners. This stock is trading up 8.8% to $5.40 in recent trading.

Today’s Range: $5.00-$5.44

52-Week Range: $1.77-$6.78

Volume: 74,000

Three-Month Average Volume: 61,738

From a technical perspective, TKMR is bouncing strongly here right off its 50-day moving average of $4.95 with above-average volume. This stock is quickly moving within range of triggering a near-term breakout trade. That trade will hit once TKMR takes out some near-term overhead resistance levels at $5.35 to $5.78 with high volume. At last check, TKMR have hit an intraday high of $5.45 and volume is just starting to surpass its three-month average action of 61,738 shares.

Traders should now look for long-biased trades in TKMR as long as it’s trending above its 50-day at $4.95, and then once it sustains a move or close above those breakout levels with volume that hits near or above 61,738 shares. If that breakout hits soon, then TKMR will set up to re-test or possibly take out its next major overhead resistance levels at $6 to $6.78.
_____________________________________________________________

TKMR is over 95,000 today on 1-10-2013.

A good PR could lead upwards.

Echo20

Talon gets its medicine from TKMR:

Talon Therapeutics Announces Review of Strategic Alternatives
Goldman Sachs Engaged as Financial Advisor

Press Release: Talon Therapeutics, Inc. – Mon, Jan 7, 2013 9:00 AM EST

RELATED QUOTES
Symbol Price Change
TLON
0.65 0.03

SOUTH SAN FRANCISCO, Calif., Jan. 7, 2013 (GLOBE NEWSWIRE) -- Talon Therapeutics (TLON), a biopharmaceutical company focused on expert and efficient clinical development of product candidates targeting hematologic malignancies and solid tumors, as well as a product candidate for the treatment-limiting skin toxicities of the EGFR-inhibitor class of cancer therapeutics, today announced that the Board has authorized a review of strategic alternatives. Goldman Sachs has been engaged to provide financial advisory services. The review of strategic alternatives may lead to a possible transaction, including the merger, business combination, or sale of the company.

No decision has been made to enter into a transaction at this time, and there can be no assurance that Talon will enter into a transaction in the future. The company does not plan to disclose or comment on developments regarding the strategic review process until further disclosure is deemed appropriate.

About Talon Therapeutics

Talon Therapeutics, Inc. is a biopharmaceutical company dedicated to seizing upon medical opportunities, efficiently and expertly leading product candidates through clinical development, and transferring value to patients, patient care providers, shareholders, corporate partners, and employees.

In addition to Marqibo(R) (vincCRIStine sulfate LIPOSOME injection) which received accelerated approval from the US FDA in August 2012, Talon has additional pipeline opportunities some of which, like Marqibo, have the potential to improve delivery and enhance the therapeutic benefits of well characterized, proven chemotherapies and enable high potency dosing without increased toxicity.

Additional information on Talon Therapeutics can be found at www.talontx.com.

The Talon Therapeutics, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=3290
__________________________________________________________

Talon is associatewd with TKMR.

Echo20

nanopatent

Very positive.

Thanks again.

Echo20

It's always good to have a little nest egg available.

It isn't meant for anything at the moment but is just sitting on the "shelf" for use if as and when needed.

Such a shelf offer could dilute the shares of TKMR at this time.

and an agent to field any complaints?

There could be an interest from ALNY on TKMR and that could spring
interest from Bristol Myers Squib and or Merck as they are staulking TKMR.

Dilution or buyout?

Still no mention of payment from ALNY!

Still no PR in 37 days.

Echo20

Nanopatent

This looks like TKMR is putting out 50 million shares of special TKMR shelf offering.

Similar to NNVC?

That could put TKMR at 64 million shares at this time.

Thoughts?

TKMR has a lot of money in hand. Could this be someone is thinking of buying TKMR? At what price. The Yahoo board member stated $7.00 per share. More shares?

Echo20

nanopatent,

What is this for?

Takeover?

Buyout?

Echo20

As filed with the Securities and Exchange Commission on January 4, 2013
Registration No. 333-



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549


Form F-10
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933


TEKMIRA PHARMACEUTICALS CORPORATION

http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=8643885

Surf144, Nanopatent,

The appointment of this agent for legal matters by Tekmira looks like legal action is approaching.

Could that be a law suit?
Takeover bid?

FORM F-X
APPOINTMENT OF AGENT FOR SERVICE OF
PROCESS AND UNDERTAKING

Process or Undertaking?

NATIONAL REGISTERED AGENTS, INC.
as Agent for Service of Process for Tekmira Pharmaceuticals Corporation.


By: /s/ Kathleen C. Gariepy
Name: Kathleen C.Gariepy




The stock price went up?

This came out at 4:30PM after the market closed on Friday.

Echo20

No PR. From TKMR in 35 days.

Echo20

No PR from TKMR in 32 days.

Could be interesting:

EBOLA

MARQUIBO

LIVER CANCER STUDIES (reduction in liver tumors in Phase One)

Alcoholic Treatment

3-4 PHASE ONE CLINICAL TRIALS PASSED with ALNY and TALON.

Being Followed by Bristol Meyers Squib and Merck.


Marina.(The exclusive rights were purchased for $300k from Marina on their sec filing)

Happy New Year

Echo20

from Yahoo TKMR Board:

Tekmira Pharmaceuticals Corp Message Board (Yahoo)

• The exclusive rights were purchased for $300k from Marina on their sec filing.mcallisterstevenj by mcallisterstevenj . Dec 1, 2012 2:09 PM . Permalink
sounds like tekmira stoled these for that price,but marina needs money and tekmira is cash rich on settlement.Marina filed the amount with the SEC on Friday or go to their news section on Yahoo.
Sentiment: Strong Buy


Re: The exclusive rights were purchased for $300k from Marina on their sec filing.peterd96 by peterd96 . Dec 4, 2012 11:08 AM . Permalink

Did this stock become a value play overnight along with outstanding biotech potential?

Is ...
Did this stock become a value play overnight along with outstanding biotech potential? Is it really just 14 million shares with float around 10-12 million?
__________________________________________________________________
? Re: Re: The exclusive rights were purchased for $300k from Marina on their sec filing.

wbart21 by wbart21 . Dec 4, 2012 5:00 PM . Permalink
yes it did... with warrants/options it's another 1mm+,but tradeable float is right whe...
yes it did... with warrants/options it's another 1mm+,but tradeable float is right where you peg it.
The $65mm has been recv'd and once counsel is paid they'll be around $50mm at year end.They get another 10mm from alny next year in milestones and the Ebola contract work for the gov't is done with a margin so that should cover 2013 burn and they should end next year with apprx the same cash balance as this year!
That of course also assumes NO licensing deals over the coming 11 months(bad assumption imo ;) as they now fully control LNP delivery.

The ST traders have exited and the stock is becoming oversold and with each down day moves closer to cash. Yes, I am bullish on this stock especially down here in the $4s= very good value imo. Once the RNAi spark is re lit this stock will do very well.
_____________________________________________________________


From Yahoo


Echo20

_____________________________________________________________

Tekmira Pharmaceuticals Corp Message BoardBack To Board Search Keyword in Tekmira Pharmaceuticals Corp Message Board All Yahoo!

message boards Search Advanced Search
Within Fields: Subject Message Body Matching: Topics Only Topics And Messages Posting: Any Date Within the range:
Start a New Topic View: Summary | Expanded
As: Threaded | Message List Previous topic | Next topic
Tekmira to be Acquired - News coming by Wensday they recieved the Settlement Check.

medtechforty by medtechforty . Nov 26, 2012 2:59 PM . Permalink
Should see at least $8 as news is getting out on Pharma Cafe and sales reps.
Sentiment: Strong Sell
0 users liked this posts 0 users disliked this posts Reply Ignore User | Report Abuse
Re: Tekmira to be Acquired - News coming by Wensday they recieved the Settlement Check.

dragan7777777777 by dragan7777777777 . Nov 26, 2012 5:38 PM . Permalink
Then why "strong sell"? And, on which Cafe Pharma board TKMR is discussed?....
Then why "strong sell"? And, on which Cafe Pharma board TKMR is discussed?....
0 users liked this posts 0 users disliked this posts Reply Ignore User | Report Abuse
Re: Tekmira to be Acquired - News coming by Wensday they recieved the Settlement Check.

gregbent by gregbent . Nov 26, 2012 3:46 PM . Permalink
Minus the $13 million in legal fees ? Or something like that.
Minus the $13 million in legal fees ? Or something like that.
Sentiment: Buy
0 users liked this posts 0 users disliked this posts Reply Ignore User | Report Abuse
View Replies

Re: Re: Tekmira to be Acquired - News coming by Wensday they recieved the Settlement Check.

inplayrnai by inplayrnai . Nov 26, 2012 6:35 PM . Permalink
I know Beitec just bought out Tacere for their RNAI technology.Better get the share price ...
I know Beitec just bought out Tacere for their RNAI technology.Better get the share price up fast as an $8.00 offer is low but a start.
______________________________________________________________

Echo20

A good price would be much higher than $7.00 a share.


TKMR was at $7.00 before the court case.

$15.00 to $20.00 would be better.


Echo20

Bvcx2222,

Here it is:

Alnylam Pharma Offers $7 in Buy-out Offer for Tekmira Coming
sciencebuys by sciencebuys . Dec 12, 2012 1:26 PM . Permalink
As predicted by many as they would get their all of Tekmira's Patents and Licenced technology along with about $4.80 in cash.This would also cancell the $10M payment they will own this company possibly in 2013 and shareholders would accept the bid.Final result would be paying about $1.50 per share for the company.

By Science Buys
_________________________________________________________

Echo20

Has anyone seen what sciencebuys on yahoo finance message board posted? Was that broadcasted? Can someone tell me what exactly he said? Was it confirmed?

No PR in 27 days.


Echo20

Bvcx2222

It could be.

IT should.

The EBOLA PHASE ONE could be close to completion.

The liver tumor testing could be close also.


Echo20

Is it finally rising?

Nano-Surf

NEW YORK (AP) -- Shares of Alnylam Pharmaceuticals Inc. rose Wednesday after a Piper Jaffray analyst upgraded the shares, saying the biotechnology company should achieve several milestones in 2013.

THE SPARK: Analyst Edward Tenthoff raised his rating to "Overweight" from "Neutral," saying Alnylam has several achievements to look forward to now that it has settled a licensing dispute with Tekmira Pharmaceuticals Corp.

Tenthoff said the company should report data from a mid-stage clinical trial of its drug ALN-TTR02 in the middle of 2013, and said Alnylam hopes to start clinical trials of injected versions of two drugs in 2013.
_______________________________________________________________

Anylam has some middle Clinical Trials going into 2012 and those each passed Clinical Trial Phase One and both passed with TKMR formulas that passed Clinical Phase One Trial!!!!!


TKMR formulas have passed a few Clinical Trials Phase One already.
Many companies get picked up after passing CLINICAL TRIAL PHASE ONE SAFETY IN HUMANS.

If TKMR passes on Clinical Trial Phase One for EBOLA that will be ANOTHER PHASE ONE PASS for TKMR, not the first! There is also TALON and MARQUIBO! (3?)

This also points to the reality the TKMR is in the MONEY LANE at this time.

Echo20

Historical PR:

Tiny Tekmira Lands $65M Settlement Plus $10M in Near-Term Milestone Payments from Alnylam

On the eve of their transformational legal trial, emerging developer Tekmira Pharmaceuticals Corporation (TKMR) (TKM.TO) announced after the market close on Monday that they had settled all litigation matters between the firm and Alnylam Pharmaceuticals, Inc. (ALNY) - whose shares dropped -4.23% After Hours to $15.44 on the news.

Tekmira, which closed Monday`s session with a $70M market cap will receive $65 million within 10 days and is eligible to receive $10 million in near-term milestone payments expected to be received in 2013.

For the speculators who were betting on a positive outcome for the pending trial, the impact should be understandibly positive.

Tekmira is now funded with over $4.00 per share in cash alone thanks to their friends at Alnylam. Perhaps more importantly, observers who know the sector argue that the key settlement now positions Tekmira as the undisputed leading delivery owner of RNA interference (RNAi) therapeutics and enables them to soon to have the largest RNAi drug opportunity.
__________________________________________________________________


Before the case TKMR was at $7.00 per share. (after a reverse stock split.)

The case knocked down the price of TKMR to $3.50.

With the case over the price of TKMR could go up 100% by that alone.

TKMR now the undisputed owner of IRNA delivery could be sought after by many PHARMACEUTICAL COMPANIES.

Echo20

When the US STOP ORDER hit TKMR what happened to the
PHASE ONE HEALTHY VOLUNTEER PATIENTS that took EBOLA IRNA?

Two months and then what?


Echo20

Moler

Once there was a reverse stock split on TKMR and then TKMR was at
$7.00 a share.

Then. The court case started and the price dropped to $3.50 and then to
Under $2.00.

With. The case over TKMR could rise to over. $7.00.

Then add in $65. M.

Multiply $7.00 X 14 million shares.

Echo20

Moler,

So if you add up $71 million dollars for the whole company and add $65 million to that you do not get $136 million dollars?

When the US gave TKMR a stop order on the $140 million dollar project that did not affect TKMR so much. TKMR could be very stable also.

I thought that being in Canada that the check would take some time to clear. However a statement of receipt of $65 million dollars has not been made so far.

I think that could help.

TKMR has plans to work on 13 projects now and that could be spread too thin and so take too long to get to market and money on any one item.

Management has to take these points into consideration.

Some lottery winners go hog wild on spending.

TKMR needs to be carefull with the new money and not to spend it too soon.

Echo20

The settlement value seems to be already calculated in the price!